£12 million investment for Oxford University Innovation spin-out Nightstar
Wellcome Trust's VC arm backs an Isis spinout developing a gene therapy for inherited blindness.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Wellcome Trust's VC arm backs an Isis spinout developing a gene therapy for inherited blindness.
'Imagine a piece of software that would allow the soldiers, aid workers and government officials thrown together after a disaster to quickly and securely communicate with each other whatever device they hold in their hands....
Oxford Immunotec announces preliminary fourth quarter revenues
Oxford University Innovation announced that OxSonics has raised £2.7 million to develop therapeutic technology which uses ultrasound devices in combination with ultrasound-sensitive nanoparticles.
Immunocore has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
A new health outcomes questionnaire for the measurement of health-related quality of life.
The first clinical trial of a gene therapy for an inherited cause of progressive blindness called choroideremia has shown very promising initial results which have surpassed the expectations of the Oxford University researchers leading the study.
A surgical patch technology developed at Oxford has been featured on the BBC.
Colwiz has announced the launch of the first HTML5 interactive PDF reader.
Reviving a gene which is “turned down” after birth is potentially the key to treating Duchenne Muscular Dystrophy, an untreatable muscle-wasting condition which affects one in every 3,500 boys.